Literature DB >> 4087075

HLA-antigens in Guillain-Barré syndrome.

M Hafez, M Nagaty, Y Al-Tonbary, F A el-Shennawy, A el-Mongui, S el-Sallab, S Attia.   

Abstract

A microlymphocytotoxicity test determined serologically the frequency of HLA antigens in 32 patients with Guillain-Barré syndrome and in 234 healthy control subjects. The results demonstrated significantly increased frequencies of A3 and B8. The relative risk was estimated to be 9.6 and 4.6 for the A3 and B8 antigens, respectively. Study of the gametic association revealed weak positive linkage disequilibrium and biological association. The results are discussed, and it is concluded that the aberrant genetic make-up of the patients makes them more susceptible to develop the syndrome after exposure to the environmental factor(s).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4087075     DOI: 10.3109/01677068509102324

Source DB:  PubMed          Journal:  J Neurogenet        ISSN: 0167-7063            Impact factor:   1.250


  3 in total

Review 1.  Challenges in developing a consensus definition of neonatal sepsis.

Authors:  Matthew McGovern; Eric Giannoni; Helmut Kuester; Mark A Turner; Agnes van den Hoogen; Joseph M Bliss; Joyce M Koenig; Fleur M Keij; Jan Mazela; Rebecca Finnegan; Marina Degtyareva; Sinno H P Simons; Willem P de Boode; Tobias Strunk; Irwin K M Reiss; James L Wynn; Eleanor J Molloy
Journal:  Pediatr Res       Date:  2020-03-03       Impact factor: 3.756

Review 2.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

3.  Guillain-Barre Syndrome Associated with Gastric Cancer: Paraneoplastic Syndrome or Immunological Disorder?

Authors:  Maria Colantuoni; Elide Matano; Salvatore Alfieri; Sabino De Placido; Chiara Carlomagno
Journal:  World J Oncol       Date:  2011-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.